|
|
|
|
|
Tuesday, January 26, 2010
|
7:15 am -
8:15 am
|
|
8:15 am -
8:30 am
|
|
8:30 am -
9:30 am
|
- Explore the advantages and limitations of comparative effectiveness research as it relates to the future of health care
- Determine the structural implications for obtaining full value from comparative effectiveness
- Evaluate initiatives underway to address gaps in evidence and how the elimination of these gaps will improve overall quality of data
|
|
|
|
9:30 am -
10:30 am
|
- Hear how states are already using comparative and cost-effective research to make policy decisions
- Learn about the powerful collaboration among state Medicaid programs for the purpose of making high quality evidence available to states to support benefit design and coverage decision
- How to utilize web-based information clearing house tools to communicate policy information, new research, evidence reports and engage in online discussions
|
|
|
|
10:30 am -
11:00 am
|
|
11:00 am -
11:45 am
|
- Hear how molecular medicine is causing disruptive market changes and the opportunities and threats to incumbents
- Examine which organizations will lose and gain market share as new entrants threaten complacent organizations
- Determine how changes to today’s health care system will cause staff, organizations and lines of business to become obsolete
|
|
|
|
11:45 am -
12:30 pm
|
- What will this new integrated model for pharmacogenetics and drug discovery look like?
- What Rx/Dx partnership incentives can we employ to achieve financial and equivalent goal congruence?
- What is the value of a biomarker that enables a therapy to an equivalent or higher ROI than OSFA?
- What pricing and outcomes models could be utilized to optimize the clinical benefit of targeted therapy and minimize the lag of diagnostic test adoption?
|
|
|
|
12:30 pm -
1:55 pm
|
- Understanding the definition of personalized medicine , the role of accurate diagnosis and how it will evolve in the future
- Recognize the challenges of the consumer market: IP, regulation and acceptance by the research and medical fields
- Defining scientific imperatives associated with personalized medicine and how policy decisions can affect them
|
|
|
|
2:00 pm -
3:00 pm
|
- Could payments based on value stimulate the adoption of personalized medicine?
- How does reimbursement look today?
- Development of metrics of payment models to incentivize adoption
|
|
|
|
3:00 pm -
3:15 pm
|
|
3:15 pm -
4:00 pm
|
- Do family members have access to results of a person's genetic testing?
- Is it possible to use a person's "risk profile," as shown by genetic testing, against a person?
- What does the Genetic Information Nondiscrimination Act (GINA) cover and leave out?
|
|
|
|
4:00 pm -
4:45 pm
|
- Defining scientific imperatives associated with personalized medicine through a case study review: how policy decisions and evolving partnerships can affect them, both positively and negatively
|
|
|
|
|
4:45 pm
|
|
|
|
|
|
|
Printer Friendly
Email A Colleague
Bookmark Page
